351 related articles for article (PubMed ID: 28196522)
1. XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.
Camus V; Miloudi H; Taly A; Sola B; Jardin F
J Hematol Oncol; 2017 Feb; 10(1):47. PubMed ID: 28196522
[TBL] [Abstract][Full Text] [Related]
2. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
Jardin F; Pujals A; Pelletier L; Bohers E; Camus V; Mareschal S; Dubois S; Sola B; Ochmann M; Lemonnier F; Viailly PJ; Bertrand P; Maingonnat C; Traverse-Glehen A; Gaulard P; Damotte D; Delarue R; Haioun C; Argueta C; Landesman Y; Salles G; Jais JP; Figeac M; Copie-Bergman C; Molina TJ; Picquenot JM; Cornic M; Fest T; Milpied N; Lemasle E; Stamatoullas A; Moeller P; Dyer MJ; Sundstrom C; Bastard C; Tilly H; Leroy K
Am J Hematol; 2016 Sep; 91(9):923-30. PubMed ID: 27312795
[TBL] [Abstract][Full Text] [Related]
3. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.
Camus V; Stamatoullas A; Mareschal S; Viailly PJ; Sarafan-Vasseur N; Bohers E; Dubois S; Picquenot JM; Ruminy P; Maingonnat C; Bertrand P; Cornic M; Tallon-Simon V; Becker S; Veresezan L; Frebourg T; Vera P; Bastard C; Tilly H; Jardin F
Haematologica; 2016 Sep; 101(9):1094-101. PubMed ID: 27479820
[TBL] [Abstract][Full Text] [Related]
4. The nuclear export protein XPO1 - from biology to targeted therapy.
Azmi AS; Uddin MH; Mohammad RM
Nat Rev Clin Oncol; 2021 Mar; 18(3):152-169. PubMed ID: 33173198
[TBL] [Abstract][Full Text] [Related]
5. A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma.
Durand M; Cabaud Gibouin V; Duplomb L; Salmi L; Caillot M; Sola B; Camus V; Jardin F; Garrido C; Jego G
J Exp Clin Cancer Res; 2024 May; 43(1):148. PubMed ID: 38773631
[TBL] [Abstract][Full Text] [Related]
6. STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma.
Miloudi H; Leroy K; Jardin F; Sola B
Cell Signal; 2018 Jun; 46():76-82. PubMed ID: 29501729
[TBL] [Abstract][Full Text] [Related]
7. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.
Walker JS; Hing ZA; Harrington B; Baumhardt J; Ozer HG; Lehman A; Giacopelli B; Beaver L; Williams K; Skinner JN; Cempre CB; Sun Q; Shacham S; Stromberg BR; Summers MK; Abruzzo LV; Rassenti L; Kipps TJ; Parikh S; Kay NE; Rogers KA; Woyach JA; Coppola V; Chook YM; Oakes C; Byrd JC; Lapalombella R
J Hematol Oncol; 2021 Jan; 14(1):17. PubMed ID: 33451349
[TBL] [Abstract][Full Text] [Related]
8. Protein biomarkers for response to XPO1 inhibition in haematologic malignancies.
Totiger TM; Chaudhry S; Musi E; Afaghani J; Montoya S; Owusu-Ansah F; Lee S; Schwartz G; Klimek V; Taylor J
J Cell Mol Med; 2023 Feb; 27(4):587-590. PubMed ID: 36722323
[TBL] [Abstract][Full Text] [Related]
9. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.
Camus V; Sarafan-Vasseur N; Bohers E; Dubois S; Mareschal S; Bertrand P; Viailly PJ; Ruminy P; Maingonnat C; Lemasle E; Stamatoullas A; Picquenot JM; Cornic M; Beaussire L; Bastard C; Frebourg T; Tilly H; Jardin F
Leuk Lymphoma; 2016 Sep; 57(9):2171-9. PubMed ID: 26883583
[TBL] [Abstract][Full Text] [Related]
10. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.
Hing ZA; Fung HY; Ranganathan P; Mitchell S; El-Gamal D; Woyach JA; Williams K; Goettl VM; Smith J; Yu X; Meng X; Sun Q; Cagatay T; Lehman AM; Lucas DM; Baloglu E; Shacham S; Kauffman MG; Byrd JC; Chook YM; Garzon R; Lapalombella R
Leukemia; 2016 Dec; 30(12):2364-2372. PubMed ID: 27323910
[TBL] [Abstract][Full Text] [Related]
11. Exportin 1-mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma.
Caillot M; Miloudi H; Taly A; Profitós-Pelejà N; Santos JC; Ribeiro ML; Maitre E; Saule S; Roué G; Jardin F; Sola B
Mol Oncol; 2023 Dec; 17(12):2546-2564. PubMed ID: 36727672
[TBL] [Abstract][Full Text] [Related]
12. EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas.
Maracaja DLV; Puthenpura V; Pels SG; O'Malley DP; Sklar JL; Finberg KE; Xu ML
Appl Immunohistochem Mol Morphol; 2020; 28(10):725-730. PubMed ID: 31789821
[TBL] [Abstract][Full Text] [Related]
13.
Miloudi H; Bohers É; Guillonneau F; Taly A; Gibouin VC; Viailly PJ; Jego G; Grumolato L; Jardin F; Sola B
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33007990
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
Schmidt J; Braggio E; Kortuem KM; Egan JB; Zhu YX; Xin CS; Tiedemann RE; Palmer SE; Garbitt VM; McCauley D; Kauffman M; Shacham S; Chesi M; Bergsagel PL; Stewart AK
Leukemia; 2013 Dec; 27(12):2357-65. PubMed ID: 23752175
[TBL] [Abstract][Full Text] [Related]
15. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
[TBL] [Abstract][Full Text] [Related]
16. Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.
Taylor J; Sendino M; Gorelick AN; Pastore A; Chang MT; Penson AV; Gavrila EI; Stewart C; Melnik EM; Herrejon Chavez F; Bitner L; Yoshimi A; Lee SC; Inoue D; Liu B; Zhang XJ; Mato AR; Dogan A; Kharas MG; Chen Y; Wang D; Soni RK; Hendrickson RC; Prieto G; Rodriguez JA; Taylor BS; Abdel-Wahab O
Cancer Discov; 2019 Oct; 9(10):1452-1467. PubMed ID: 31285298
[TBL] [Abstract][Full Text] [Related]
17. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D
Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897
[TBL] [Abstract][Full Text] [Related]
18. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
[No Abstract] [Full Text] [Related]
19. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
Benkova K; Mihalyova J; Hajek R; Jelinek T
Blood Rev; 2021 Mar; 46():100758. PubMed ID: 32972802
[TBL] [Abstract][Full Text] [Related]
20. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
